Urinary albumin excretion with sitagliptin compared to sulfonylurea as add on to metformin in type 2 diabetes patients with albuminuria: A real-world evidence study

Journal of Diabetes and its Complications

Volumn 30, Issue 7, 2016, Pages 1354-1359

  Goldshtein, Inbal ^a   Karasik, Avraham ^b,c   Melzer Cohen, Cheli ^a   Engel, Samuel S ^d   Yu, Shengsheng ^d   Sharon, Ofer ^e   Brodovicz, Kimberly ^d   Gadir, Noga ^e   Katzeff, Harvey L ^d   Radican, Larry ^d   Chodick, Gabriel ^a   Shalev, Varda ^a,c   Tunceli, Kaan ^d  

^a MACCABI HEALTHCARE SERVICES   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d MERCK RESEARCH LABORATORIES   (United States)

^e MSD Israel Co Ltd   (Israel)

Author keywords

Albuminuria; DPP 4 inhibitors; Nephropathy; Sitagliptin; Sulfonylurea

Indexed keywords

ALBUMIN; CREATININE; HEMOGLOBIN A1C; METFORMIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT;

ADD ON THERAPY; ADULT; AGED; ALBUMINURIA; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE URINE LEVEL; DISEASE DURATION; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; SOCIAL STATUS; URINARY EXCRETION; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COMPLICATION; ISRAEL; URINE;

AGED; ALBUMINURIA; CREATININE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; ISRAEL; MALE; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES; SITAGLIPTIN PHOSPHATE; SULFONYLUREA COMPOUNDS;

EID: 84990960882     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2016.05.012     Document Type: Article

References (20)

1. Alter, M.L., Ott, I.M., von Websky, K., Tsuprykov, O., Sharkovska, Y., Krause-Relle, K., Hocher, B., DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney & Blood Pressure Research 36:1 (2012), 119–130.
2. R: A Language and Environment for Statistical Computing [computer program]. 2013, R Foundation for Statistical Computing, Vienna, Austria.
3. Ayodele, O.E., Alebiosu, C.O., Salako, B.L., Diabetic nephropathy–a review of the natural history, burden, risk factors and treatment. Journal of the National Medical Association 96:11 (2004), 1445–1454.
4. Chodick, G., Heymann, A.D., Shalev, V., Kookia, E., The epidemiology of diabetes in a large Israeli HMO. European Journal of Epidemiology 18:12 (2003), 1143–1146.
5. Cohen, C.M., Chodik, G., Karasik, A., Radican, L., Yu, S., Voss, B., Tunceli, K., Urinary Albumin Secretion in Type 2 Diabetes Patients (T2DM) with Albuminuria Treated with Sitagliptin as Add-On Therapy to Metformin: A Real- World Data Study. Diabetes, 63(Suppl. 1), 2014 (http://app.core-apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc8638747257. Accessed May 3, 2015).
6. Dyer, A.R., Greenland, P., Elliott, P., Daviglus, M.L., Claeys, G., Kesteloot, H., INTERMAP Research Group, Evaluation of measures of urinary albumin excretion in epidemiologic studies. American Journal of Epidemiology 160:11 (2004), 1122–1131.
7. Gansevoort, R.T., Brinkman, J., Bakker, S.J., De Jong, P.E., de Zeeuw, D., Evaluation of measures of urinary albumin excretion. American Journal of Epidemiology 164:8 (2006), 725–727.
8. Hattori, S., Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocrine Journal 58:1 (2011), 69–73.
9. Kawasaki, I., Hiura, Y., Tamai, A., Yoshida, Y., Yakusiji, Y., Ikuno, Y., Hosoi, M., Sitagliptin reduces the urine albumin-to-creatinine ratio in type 2 diabetes through decreasing both blood pressure and estimated glomerular filtration rate. Journal of Diabetes 7:1 (2015), 41–46.
10. Lachin, J.M., Viberti, G., Zinman, B., Haffner, S.M., Aftring, R.P., Paul, G., ADOPT Study Group, Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology : CJASN 6:5 (2011), 1032–1040.
11. Levey, A.S., Eckardt, K.U., Tsukamoto, Y., Levin, A., Coresh, J., Rossert, J., Eknoyan, G., Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International 67:6 (2005), 2089–2100.
12. Miler, M., Simundic, A.M., Low level of adherence to instructions for 24-hour urine collection among hospital outpatients. Biochemia medica 23:3 (2013), 316–320.
13. Mori, H., Okada, Y., Arao, T., Tanaka, Y., Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus. Journal of Diabetes Investigation 5:3 (2014), 313–319.
14. Muskiet, M.H., Smits, M.M., Morsink, L.M., Diamant, M., The gut-renal axis: Do incretin-based agents confer renoprotection in diabetes?. Nature Reviews Nephrology 10:2 (2014), 88–103.
15. Newton, C.A., Raskin, P., Blood pressure control–effects on diabetic nephropathy progression: How low does blood pressure have to be?. Current Diabetes Reports 2:6 (2002), 530–538.
16. Nosadini, R., Tonolo, G., Relationship between blood glucose control, pathogenesis and progression of diabetic nephropathy. Journal of the American Society of Nephrology: JASN 15:Suppl. 1 (2004), S1–S5.
17. Parving, H.H., Mauer, M., Ritz, E., Diabetic nephropathy. Brenner and Rector's The Kidney, 2008, WB Saunders, Boston, 1265–1298.
18. Schernthaner, G., Mogensen, C.E., Schernthaner, G.H., The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system. Diabetes & Vascular Disease Research 11:5 (2014), 306–323.
19. Tunceli, K., Goldshtein, I., Yu, S., et al. Adherence to treatment guidelines in type 2 diabetes patients failing metformin monotherapy in a real-world setting. Diabetes Management 5:1 (2015), 17–24.
20. Vaghasiya, J., Sheth, N., Bhalodia, Y., Manek, R., Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes. Regulatory Peptides 166:1–3 (2011), 48–54.